News Celldex Therapeutics, Inc.

Equities

CLDX

US15117B2025

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-23 pm EDT			5-day change	1st Jan Change
37.77 ^USD	-2.78%		-2.15%	-4.77%

Apr. 17	Sector Update: Health Care Stocks Mixed Wednesday Afternoon	MT
Apr. 17	Celldex Therapeutics Says Patient Enrollment Completed in Chronic Inducible Urticaria Treatment Study; Shares Rise	MT

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Sector Update: Health Care Stocks Mixed Wednesday Afternoon	Apr. 17	MT
Celldex Therapeutics Says Patient Enrollment Completed in Chronic Inducible Urticaria Treatment Study; Shares Rise	Apr. 17	MT
Celldex Therapeutics : Corporate Presentation	Apr. 17	PU
Celldex Announces Completion of Enrollment in Phase 2 Study of Barzolvolimab in Patients with Chronic Inducible Urticaria	Apr. 17	AQ
Celldex Therapeutics, Inc. Announces Completion of Enrollment in Phase 2 Study of Barzolvolimab in Patients with Chronic Inducible Urticaria	Apr. 17	CI
Celldex Therapeutics to Participate in the Leerink Partners Global Biopharma Conference	Mar. 08	AQ
Celldex Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters Option to Purchase Additional Shares	Mar. 06	AQ
Celldex Therapeutics to Present at TD Cowen's 44th Annual Health Care Conference	Mar. 06	AQ
Celldex Therapeutics to Present at TD Cowen’s 44th Annual Health Care Conference	Mar. 05	AQ
Celldex Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares	Mar. 05	AQ
Celldex Therapeutics Prices $400.4 Million Common Stock Offering	Mar. 01	MT
Celldex Therapeutics Announces Pricing of Upsized $400 Million Public Offering of Common Stock	Feb. 29	AQ
Celldex Therapeutics Proposes $250 Million Underwritten Common Stock Offering	Feb. 28	MT
Celldex Therapeutics Announces Proposed Public Offering of Common Stock	Feb. 28	AQ
Sector Update: Health Care Stocks Weaker Monday Afternoon	Feb. 26	MT
Celldex Therapeutics Shares Rise After Q4 Revenue Tops Estimates	Feb. 26	MT
Celldex Therapeutics Presents Positive 12 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria	Feb. 26	AQ
Sector Update: Health Care Stocks Mixed Premarket Monday	Feb. 26	MT
Celldex Therapeutics Q4 Loss Widens, Revenue Rises; Shares Up Pre-Bell	Feb. 26	MT
Celldex: Q4 Earnings Snapshot	Feb. 26	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Celldex Therapeutics, Inc.

Equities

CLDX

US15117B2025

Summary

Filters